Hormonal
GLP-1 receptor agonists (GLP-1RAs) exert neuroprotective effects in neurodegenerative diseases (Alzheimer's, Parkinson's, Multiple Sclerosis) by modulating synaptic plasticity, reducing neuroinflammation, and promoting neurogenesis, although clinical trial outcomes remain variable.
GLP-1 drugs like semaglutide and liraglutide show promise in protecting brain cells and slowing cognitive/motor decline in diseases like Alzheimer's and Parkinson's, based on strong lab studies. However, human trials have been mixed, likely due to how patients are chosen and how trials are run. If you have a neurodegenerative condition, discuss with your doctor whether the potential brain benefits outweigh the risk of stomach side effects, especially if you are frail or elderly.
GLP-1 receptor agonists (GLP-1RAs), initially approved for diabetes and obesity, are now under investigation for neuroprotective effects in a range of neurological disorders. These agents... modulate neurotransmitter release and promote neurogenesis. While preclinical studies consistently demonstrate benefits in models of Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS), clinical trial outcomes have been variable, largely owing to heterogeneity in study populations and trial design.
Why this rating
The paper is a review summarizing both robust preclinical data and mixed/variable clinical trial results, indicating moderate but inconsistent translational evidence.
Source
From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics
Akash Roy et al. · Neurotherapeutics · 2025
DOI 10.1016/j.neurot.2025.e00712
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →